BillionToOne

BillionToOne

QCT-based molecular diagnostics for prenatal, oncology

Oncology Account Executive

Full-TimePosted on 6/17/2026
$168.3k - $184.2k/yr

+ Uncapped commissions + Equity options + 4% 401(k) match

Mid
Bachelor's
South Miami, FL, USA
Remote

Must live within the defined territory and travel within it.

About the job

Requirements
  • A bachelor's degree or equivalent experience.
  • A demonstrated successful sales track record, such as Presidents Club, Chairman's Club, Rookie of the Year, or performance at or above goal for multiple quarters or years.
  • Experience selling to medical providers.
  • Experience selling medical diagnostics or medical or surgical devices.
  • Residence within the defined territory and central location to the defined accounts.
  • A commitment to travel within the defined territory.
  • Excellent written and verbal organizational and communication skills, with the ability to present effectively to internal and external customers.
  • Effective time management skills and the ability to assess and prioritize opportunities.
  • The ability to assess the needs of medical professionals and staff members, with a focus on consultative sales, logistics coordination, and problem solving.
  • The ability to work independently in a startup environment with an internal drive to succeed.
  • Physician Assistant, Nurse Practitioner, or Registered Nurse candidates should have experience ordering late-stage cancer liquid biopsy tests.
Responsibilities
  • Increase revenue and drive market development through direct sales to individual oncologists.
  • Create and implement a strategic business plan to grow revenue quickly within the assigned geography.
  • Prospect effectively, cultivate new business, and maintain key relationships.

About the company

BillionToOne provides molecular diagnostic testing for prenatal screening and cancer monitoring. Its QCT technology detects and measures DNA variations at a single base-pair level, enabling precise analysis across the three billion DNA letters. The main products, Northstar Select and Northstar Response, are tests that help doctors choose the best first-line therapy and track how well treatment is working, respectively. The company markets these services to healthcare providers who perform the tests and use the results to guide patient care. Unlike some rivals, BillionToOne emphasizes high-resolution DNA assessment and scalable diagnostic services through provider partnerships, aiming to improve accuracy, speed, and access. Its mission is to make molecular testing more accurate, efficient, and accessible to all, driven by growth, equality, and teamwork.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Menlo Park, California

Founded

2016

Get referred to BillionToOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $109.4 million, up 64% year over year.
  • Northstar Origin launched September 1, 2026, targeting cancer-of-unknown-primary diagnostics.
  • Unity Confirm and 130-gene panel expanded August 2026 broaden prenatal adoption.

What critics are saying

  • Illumina sued May 7, 2026, alleging UNITY infringes three patents.
  • An injunction or damages award could cripple prenatal revenue before 2027.
  • CEO Oguzhan Atay sold all directly held shares on September 14, 2026.

What makes BillionToOne unique

  • QCT counts single DNA molecules, enabling rare-variant detection competitors miss.
  • Unity and Northstar cover prenatal and oncology workflows from one diagnostics platform.
  • Expanded 130-gene Unity panel and Northstar Origin deepen product moat.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Sep 21st, 2026
BillionToOne SVP sells $138K in shares under pre-set trading plan, retains $2.4M stake

John Roderick Ten Bosch, SVP of Laboratory Operations at BillionToOne, sold 1,416 shares of Class A Common Stock on 9 September 2026 at a weighted average price of $97.54, according to an SEC filing. The transaction was conducted under a Rule 10b5-1 plan adopted in June 2026. Following the sale, Ten Bosch retains 25,051 shares valued at $2.4 million. The sale represents a single-digit percentage of his total holdings. BillionToOne, a Menlo Park-based diagnostics company, has a $4.6 billion market capitalisation. The company reported revenue of $397 million and net income of $32 million. Revenue surged 64% year over year in the second quarter, with analysts expecting approximately 37% annualised growth over the next two years.

Yahoo Finance
Sep 17th, 2026
BillionToOne CEO sells entire direct stake for $3M via pre-planned trading arrangement

BillionToOne CEO Oguzhan Atay sold 30,331 Class A shares on 14 September 2026 for approximately $3 million, liquidating his entire directly held stake in the company. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted in June 2026. The transaction primarily involved a cashless exercise of 24,999 options at $2.80 per share, with immediate sale of resulting shares. Atay's spouse sold an additional 5,332 shares. The weighted average sale price was $99.91. Despite disposing of directly held shares, Atay retains about 500,000 fully vested stock options and holds approximately 157,000 shares indirectly through his spouse. The Menlo Park-based molecular diagnostics company reported $109.4 million revenue in Q2 2026, representing 64% year-over-year growth, with full-year revenue forecast between $450 million and $465 million.

PR Newswire
Sep 1st, 2026
BillionToOne launches Northstar Origin liquid biopsy test to identify cancer tissue of origin

BillionToOne has launched Northstar Origin, a liquid biopsy add-on test that predicts tissue of origin from circulating cell-free DNA for patients with cancer of unknown primary or uncertain cancer diagnosis. The test requires no additional tissue or separate blood draws beyond what's already collected for therapy selection. In a validation study of 1,578 patients, Northstar Origin identified the correct tissue of origin as its top prediction in 87% of cases and within its top three predictions in 91% of cases. The classifier was developed using 6,025 blood samples from advanced cancer patients. The company also expanded its Northstar Select panel from 84 to 102 genes, adding 18 new genes including MTAP deletion. The test is designed to help community oncologists make diagnostic decisions, as roughly 3-5% of new cancer diagnoses present as cancer of unknown primary.

Yahoo Finance
Aug 28th, 2026
BillionToOne CTO sells $1M in shares under pre-planned trading arrangement

David Tsao, co-founder and chief technology officer of BillionToOne, sold 10,000 shares of Class A Common Stock for $1 million on 25 August 2026. The transaction involved a cashless exercise of fully vested stock options at $2.80 per share, with the resulting shares sold at a weighted average price of $100. The sale was executed under a Rule 10b5-1 trading plan adopted in March 2026, indicating it was pre-scheduled rather than discretionary. Tsao retains 1,000 direct shares and 580,000 stock options. BillionToOne, a Menlo Park-based molecular diagnostics company, reported second-quarter revenue of $109.4 million, representing 64% year-over-year growth. The company has a market capitalisation of $4.4 billion and generated $397.4 million in trailing 12-month revenue with $33.5 million in net income.

Yahoo Finance
Aug 6th, 2026
BillionToOne reports $109.4M Q2 revenue, up 64% year-over-year, reiterates 2026 guidance

BillionToOne, a molecular diagnostics company, reported second-quarter 2026 revenue of $109.4 million, up 64% from $66.6 million in the same period last year. Prenatal clinical testing revenue reached $94.2 million, whilst oncology testing revenue surged 176% to $13.7 million. The company delivered 196,000 tests during the quarter, a 35% increase year-over-year. Gross profit margin improved to 70% from 65%. BillionToOne posted operating income of $5.5 million, compared to a $1.6 million loss in Q2 2025. The firm reiterated its full-year 2026 revenue guidance of $450 million to $465 million, representing 48% to 52% growth over 2025. BillionToOne announced plans to expand its Unity Fetal Risk Screen with a 130-gene panel launching 17 August 2026.

INACTIVE